Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rabies virus inactivated antigen, A is an inactivated viral vaccine used for active immunization against rabies. It is indicated for both pre-exposure prophylaxis (PrEP) in individuals at high risk of exposure and post-exposure prophylaxis (PEP) following a potential rabies exposure. The vaccine works by stimulating the immune system to produce rabies virus-neutralizing antibodies (RVNA), which target the viral glycoprotein (G protein) to prevent the virus from infecting the central nervous system. Common formulations include the Human Diploid Cell Vaccine (HDCV) and the Purified Chick Embryo Cell Vaccine (PCECV). It is typically administered via intramuscular injection.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on rabies virus inactivated antigen, A.